This competition has up to £10m to develop innovative healthcare products, technologies and processes. These can include, for example: disease prevention and proactive management of health and chronic conditions earlier, better detection and diagnosis of disease leading to better patient outcomes, and tailored treatments that either change the underlying disease or offer potential cures.
Competition closes: 26 August 2021, 11am
Applicants notified: 02 October (invite to interview); 30 October (interview outcome)
Interview panel week: 19 October 2021
Project start date & duration: 01 April 2022; between 12 to 36 months
The aim of this early and late-stage competition is to enable businesses to create a data package that can support the further development of their products. Projects can include:
- experimental evaluation (at laboratory scale)
- use of in vitro and in vivo models to evaluate proof of concept or safety
- exploring potential production mechanisms
- product development planning
- intellectual property protection
- demonstrating of clinical utility and effectiveness
- demonstrating of safety and efficacy (including phase 1 and 2 clinical trials)
- regulatory planning
Projects must focus developing a product or process that is an innovative solution to a defined health or care challenge.
Early-stage: The aim of an early-stage award is to create a data package that is sufficient to support the testing of your product or process in a clinical setting or other relevant environment.
Late-stage: The late-stage award is designed to test a well-developed concept and show its effectiveness in a clinical setting or other relevant environment.
Your project must build on prior credible research on a product prototype or process. This is likely to have included a demonstration or validation in an appropriate model system
Projects can focus on any health and care sector or discipline. Applications that support innovations in the following areas are welcomed:
- child health technologies;
- innovations that support clinical trials in the UK;
- biomedical innovations that combat the threat of antimicrobial resistance.
Projects can align with one of these innovation areas (non-exhaustive list):
- medical technologies and devices;
- stratified healthcare;
- advanced therapies (gene and cell therapies);
- digital health;
- drug discovery;
Projects that will not be funded
- in scope for the Biomedical Catalyst feasibility or primer awards.
- not related to human life sciences
- already on the market
- laboratory accreditation
- distribution or marketing activity, post-marketing studies and post-marketing surveillance
- dependent on export performance – for example giving a subsidy to a baker on the condition that they export a certain quantity of bread to another country.
- dependent on domestic inputs usage- for example if they insisted that a baker use 50% UK flour in their product
We will not support innovation projects conducted to anything less than the highest standards of animal welfare.
- Subsidy Control and EC State Aid funding rules apply
- Project must be led by a UK business of any size and collaborators must be UK based organisations
- R&D work must be carried out in the UK and project results exploited from UK.
- Subcontractors can be from UK/overseas, with costs justified and appropriate to the total eligible project costs.
Total eligible project costs between £250,000 and £4M (£18M pot)
For Industrial Research projects.
- Micro/small business <70%
- Medium sized business <60%
For Experimental Development projects.
- Micro/small business <45%
- Medium sized business <35%
Research organisations in your consortium can share up to 50% of the total eligible project costs.